News & Announcements
Improved Academic Performance and Medication Rebound in Patients with ADHD Following the Use of Vayarin®, a Multi-Year, Real-World Retrospective Study
January 25, 2017
New Retrospective Study to be Presented at The American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting January 13-15, 2017 in Washington DC
BALTIMORE, Jan. 24, 2017 (GLOBE NEWSWIRE) -- In a release issued under the same headline January 10, 2017 by VAYA Pharma, please note that in the first paragraph under Results at a Glance, "38 percent of patients who suffer" should read "65 percent of patients who suffer." The corrected release follows:
Up to 75 percent of individuals with Attention Deficit Hyperactivity Disorder (ADHD) experience emotional dysregulation, according to Research in Developmental Disabilities. Emotional dysregulation is characterized by rapid, poorly controlled shifts in emotion, mood swings and behavioral outbursts. Studies have shown that individuals with ADHD and emotional dysregulation have significantly more impaired peer relationships, family life and academic performance than those diagnosed with ADHD alone. A new multi-year retrospective study initiated by Robert Chudnow, M.D. at Texas Child Neurology looked at patients’ reports on long-term impact of Vayarin® PS-Omega-3 medical food on patients with ADHD along with indicators for emotional dysregulation, academic performance and medication rebound. A poster presentation about the study will be featured at the American Professional Society of ADHD and Related Disorders (APSARD) annual meeting January 13-15, 2017 in Washington, DC.
Results at a Glance
The lead investigators found that 68 percent of children with ADHD who added Vayarin® to their ADHD management routine reported general improvements following a short and long-term administration period (an average of six and 36 months, respectively) of the medical food. For example, patients reported improvements in their academic performance (58 percent) and emotional regulation (51 percent). Emotional dysregulation is a component of ADHD that has been shown to predict poor long-term clinical and educational outcomes in early-adulthood, such as academic performance. Additionally, 65 percent of patients who suffer from medication rebound reported improvement in the rebounding effect. Medication rebound is characterized by the re-emergence of ADHD symptoms after prescription medications – including stimulants – wear off.
Click here to read the rest of the story on Globe Newswire